• Explore /
  • Videos & Slides
  • / TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).

TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).

Abstract Video & Slides

Presenter

Michael Hofman

Michael S Hofman, FRACP, MBBS

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2022 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03392428

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5000)

DOI

10.1200/JCO.2022.40.16_suppl.5000

Abstract #

5000

Abstract Disclosures

Similar Videos & Slides

Speaker: James Patrick Buteau, MD FRCPC

Speaker: Tim Reason

Speaker: Michael S Hofman, FRACP, MBBS

Speaker: Cora N. Sternberg, FACP, MD